Wells Fargo analyst Mohit Bansal maintained a Buy rating on Regeneron (REGN – Research Report) yesterday and set a price target of $900.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Mohit Bansal’s rating is based on the potential growth and strategic initiatives undertaken by Regeneron. The company is optimistic about its pipeline and upcoming catalysts in the latter half of 2025, which are expected to drive upside despite potential volatility. Regeneron is actively managing the pressures from biosimilar competition to Eylea, maintaining a significant market share and exploring sales growth opportunities through product enhancements.
Additionally, the progress in launching Dupixent for COPD and its inclusion in the GOLD guidelines suggests an accelerating uptake in 2025. The introduction of a dividend indicates confidence in future cash flows, and pivotal readouts expected in 2025, such as those for COPD and melanoma treatments, could significantly enhance Regeneron’s market position. Overall, these factors contribute to a positive outlook for Regeneron, justifying the Buy rating.
In another report released yesterday, Morgan Stanley also maintained a Buy rating on the stock with a $1,150.00 price target.